NASDAQ:CLNN Clene - CLNN Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Clene Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $1.20 +0.02 (+1.35%) (As of 03/21/2023 01:52 PM ET) Add Compare Share Share Today's Range$1.17▼$1.2050-Day Range$1.07▼$1.6252-Week Range$0.87▼$5.13Volume94,730 shsAverage Volume1.20 million shsMarket Capitalization$92.00 millionP/E RatioN/ADividend YieldN/APrice Target$11.33 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Clene MarketRank™ ForecastAnalyst RatingModerate Buy2.86 Rating ScoreUpside/Downside855.6% Upside$11.43 Price TargetShort InterestHealthy6.65% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.41Based on 14 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.46) to ($0.38) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.25 out of 5 starsMedical Sector308th out of 988 stocksPharmaceutical Preparations Industry134th out of 482 stocks 3.4 Analyst's Opinion Consensus RatingClene has received a consensus rating of Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.43, Clene has a forecasted upside of 855.6% from its current price of $1.20.Amount of Analyst CoverageClene has only been the subject of 4 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted6.65% of the float of Clene has been sold short.Short Interest Ratio / Days to CoverClene has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Clene has recently decreased by 37.87%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldClene does not currently pay a dividend.Dividend GrowthClene does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CLNN. Previous Next 3.0 News and Social Media Coverage News SentimentClene has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Clene this week, compared to 2 articles on an average week.Search Interest39 people have searched for CLNN on MarketBeat in the last 30 days. This is an increase of 39% compared to the previous 30 days.MarketBeat Follows10 people have added Clene to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Clene insiders have not sold or bought any company stock.Percentage Held by Insiders28.70% of the stock of Clene is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 5.86% of the stock of Clene is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Clene are expected to grow in the coming year, from ($0.46) to ($0.38) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Clene is -2.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Clene is -2.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioClene has a P/B Ratio of 29.90. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Clene (NASDAQ:CLNN) StockClene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; ongoing Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a planned Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company's products also include CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to accelerate wound healing; CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease, such as COVID-19 and to provide immune support for symptom resolution; and CNM-PtAu7, a gold-platinum CSN therapeutic for oncology applications. It also markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.Read More Receive CLNN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Clene and its competitors with MarketBeat's FREE daily newsletter. Email Address CLNN Stock News HeadlinesMarch 19, 2023 | uk.investing.comClene earnings beat by $0.11, revenue topped estimatesMarch 18, 2023 | americanbankingnews.comClene Inc. to Post Q1 2023 Earnings of ($0.16) Per Share, HC Wainwright Forecasts (NASDAQ:CLNN)March 21, 2023 | PressReach (Ad)Stocks Positioned For The YearThis breakthrough stock has bright future this decade.March 17, 2023 | americanbankingnews.comClene Inc. (NASDAQ:CLNN) to Post Q2 2023 Earnings of ($0.12) Per Share, HC Wainwright ForecastsMarch 16, 2023 | finance.yahoo.comClene Appoints Neurology Expert to Executive TeamMarch 15, 2023 | americanbankingnews.comClene (NASDAQ:CLNN) Stock Rating Reaffirmed by HC WainwrightMarch 13, 2023 | americanbankingnews.comClene Inc. (NASDAQ:CLNN) Receives Average Rating of "Moderate Buy" from AnalystsMarch 12, 2023 | americanbankingnews.comClene (NASDAQ:CLNN) PT Raised to $8.00March 21, 2023 | PressReach (Ad)Stocks Positioned For The YearThis breakthrough stock has bright future this decade.March 12, 2023 | americanbankingnews.comClene (NASDAQ:CLNN) Now Covered by EF Hutton Acquisition Co. IMarch 8, 2023 | finance.yahoo.comClene to Announce New CNM-Au8® Data From the Healey ALS Platform TrialMarch 7, 2023 | finance.yahoo.comClene Nanomedicine to Participate in Roth’s 35th Annual Healthcare Conference and Renmark Virtual Non-Deal Roadshow SeriesMarch 6, 2023 | finance.yahoo.comNew Data Show CNM-Au8® Preserved ALS Patient Function and Slowed Disease Progression in the Open-Label Extension of the Phase 2 RESCUE-ALS TrialFebruary 13, 2023 | finance.yahoo.comClene Inc. (CLNN) Stock Historical Prices & Data - Yahoo FinanceFebruary 13, 2023 | finance.yahoo.comClene Reports New Data from the VISIONARY-MS Phase 2 Study in Multiple Sclerosis Demonstrating CNM-Au8® Treatment Improved Brain Neuronal Structural IntegrityJanuary 11, 2023 | finance.yahoo.comClene Nanomedicine Announces Participation in Renmark Virtual Non-Deal Roadshow Series on January 18 and January 23December 27, 2022 | finance.yahoo.comClene Nanomedicine Reports Topline Results of Phase 2 COVID-19 Study of CNM-ZnAgDecember 12, 2022 | finance.yahoo.comClene Announces Closing of $5 Million Debt Facility from the State of MarylandOctober 31, 2022 | finance.yahoo.comClene Announces $10.8 Million Registered Direct Offering and $5 Million Debt Facility from the State of MarylandOctober 10, 2022 | finance.yahoo.comNew Drugs And Therapies Are Giving MS And ALS Sufferers New Hope - Yahoo FinanceOctober 5, 2022 | marketwatch.comClene Shares Slip Again After Analysts Weigh in on ALS Setback >CLNN - MarketWatchOctober 4, 2022 | benzinga.comClene shares are trading lower after Oppenheimer downgraded the stock from Outperform to Perform. - Clene (NASDAQ:CLNN) - BenzingaOctober 3, 2022 | investing.comU.S. stocks higher at close of trade; Dow Jones Industrial Average up 2.66% By Investing.com - Investing.comOctober 3, 2022 | benzinga.comClene Reports Topline Results Demonstrating Survival Signal For CNM-Au8® In Healey ALS Platform Trial; Co - BenzingaOctober 3, 2022 | benzinga.comClene shares are trading lower after the company announced topline results in the Healey ALS Platform tri - BenzingaOctober 3, 2022 | seekingalpha.comCLNN stock slips as lead asset fails in ALS study (NASDAQ:CLNN) - Seeking AlphaOctober 3, 2022 | seekingalpha.comAvenue, Myovant top healthcare gainers; Clene, Apellis lead losers' pack - Seeking AlphaSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive CLNN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Clene and its competitors with MarketBeat's FREE daily newsletter. Email Address CLNN Company Calendar Last Earnings11/08/2021Today3/21/2023Next Earnings (Estimated)5/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CLNN CUSIPN/A CIK1822791 Webclene.com Phone801-676-9695FaxN/AEmployees95Year FoundedN/APrice Target and Rating Average Stock Price Forecast$11.43 High Stock Price Forecast$17.00 Low Stock Price Forecast$6.00 Forecasted Upside/Downside+860.5%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($0.45) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-29,920,000.00 Net Margins-6,325.16% Pretax Margin-6,325.16% Return on Equity-4,043.36% Return on Assets-107.13% Debt Debt-to-Equity Ratio5.96 Current Ratio2.11 Quick Ratio2.10 Sales & Book Value Annual Sales$470,000.00 Price / Sales193.14 Cash FlowN/A Price / Cash FlowN/A Book Value$0.04 per share Price / Book29.50Miscellaneous Outstanding Shares76,930,000Free Float54,850,000Market Cap$90.78 million OptionableNot Optionable Beta0.39 Key ExecutivesMr. Robert Etherington MBA (Age 55)CEO, Pres & Director Comp: $820.13kMr. Mark G. Mortenson (Age 64)Co-Founder & Chief Science Officer Comp: $628.43kDr. Robert Glanzman M.D. (Age 65)Chief Medical Officer Comp: $573.39kMr. Morgan R. Brown CPA (Age 54)CPA, M.B.A., MBA, Chief Financial Officer Mr. Jerry Miraglia J.D.Gen. Counsel & Corp. Sec.Mr. Michael T. HotchkinChief Devel. OfficerMs. Mary Anne McneilHead of HRDr. Tae Heum Jeong D. Mgt. (Age 51)Consultant More ExecutivesKey CompetitorsLarimar TherapeuticsNASDAQ:LRMRXBiotechNASDAQ:XBITMediciNovaNASDAQ:MNOVDisc Medicine OpcoNASDAQ:IRONAffimedNASDAQ:AFMDView All CompetitorsInsiders & InstitutionsParallax Volatility Advisers L.P.Sold 27,600 shares on 2/27/2023Ownership: 0.000%Atom Investors LPBought 123,051 shares on 2/15/2023Ownership: 0.167%Millennium Management LLCSold 92,947 shares on 2/15/2023Ownership: 0.159%Belvedere Trading LLCBought 36,100 shares on 2/15/2023Ownership: 0.000%Boothbay Fund Management LLCSold 240,500 shares on 2/15/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions CLNN Stock - Frequently Asked Questions Should I buy or sell Clene stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Clene in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CLNN shares. View CLNN analyst ratings or view top-rated stocks. What is Clene's stock price forecast for 2023? 7 brokers have issued 1 year price objectives for Clene's shares. Their CLNN share price forecasts range from $6.00 to $17.00. On average, they predict the company's stock price to reach $11.43 in the next twelve months. This suggests a possible upside of 868.5% from the stock's current price. View analysts price targets for CLNN or view top-rated stocks among Wall Street analysts. How have CLNN shares performed in 2023? Clene's stock was trading at $1.00 at the beginning of the year. Since then, CLNN shares have increased by 18.0% and is now trading at $1.18. View the best growth stocks for 2023 here. Are investors shorting Clene? Clene saw a drop in short interest in the month of February. As of February 28th, there was short interest totaling 1,870,000 shares, a drop of 37.9% from the February 13th total of 3,010,000 shares. Based on an average daily trading volume, of 926,400 shares, the short-interest ratio is presently 2.0 days. Approximately 6.7% of the company's stock are short sold. View Clene's Short Interest. When is Clene's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023. View our CLNN earnings forecast. How were Clene's earnings last quarter? Clene Inc. (NASDAQ:CLNN) issued its quarterly earnings results on Monday, November, 8th. The company reported $0.42 earnings per share for the quarter, topping analysts' consensus estimates of ($0.20) by $0.62. The firm earned $0.11 million during the quarter, compared to the consensus estimate of $0.14 million. Clene had a negative trailing twelve-month return on equity of 4,043.36% and a negative net margin of 6,325.16%. What is Clene's stock symbol? Clene trades on the NASDAQ under the ticker symbol "CLNN." Who are Clene's major shareholders? Clene's stock is owned by many different institutional and retail investors. Top institutional shareholders include Kepos Capital LP (0.47%), Susquehanna International Group LLP (0.00%), Geode Capital Management LLC (0.31%), Simplex Trading LLC (0.00%), Atom Investors LP (0.17%) and Millennium Management LLC (0.16%). Insiders that own company stock include Alison Mosca, David J Matlin, David J Matlin, General Resonance Llc, John Henry Stevens, Jonathon Gay, Robert Dee Etherington and Robert Glanzman. View institutional ownership trends. How do I buy shares of Clene? Shares of CLNN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Clene's stock price today? One share of CLNN stock can currently be purchased for approximately $1.18. How much money does Clene make? Clene (NASDAQ:CLNN) has a market capitalization of $90.78 million and generates $470,000.00 in revenue each year. The company earns $-29,920,000.00 in net income (profit) each year or ($0.45) on an earnings per share basis. How can I contact Clene? Clene's mailing address is UNIT 902 9/F LUCKY BUILDING 39 WELLINGTON STREET, HONG KONG K3, . The official website for the company is clene.com. The company can be reached via phone at 801-676-9695 or via email at ir@clene.com. This page (NASDAQ:CLNN) was last updated on 3/21/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.